Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.46 |
| ▸ | PPARG | P37231 | 13/20 | 0.46 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069940 | 0.92 | PPARA (0.46) | PPARAPPARGPPARD | |
| SCHEMBL7066090 | 0.91 | PPARG (0.43) | PPARAPPARGPPARDALDH1A1LMNA | |
| SCHEMBL7069282 | 0.88 | PPARG (0.45) | PPARAPPARGPPARDSMN1; SMN2MME | |
| SCHEMBL7070373 | 0.85 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL7067891 | 0.81 | LMNA (0.46) | PPARAPPARGPPARDALDH1A1LMNA | |
| SCHEMBL7067840 | 0.81 | PPARG (0.42) | PPARAPPARGPPARD | |
| SCHEMBL7069697 | 0.80 | PPARG (0.41) | PPARAPPARGPPARDSMN1; SMN2NOTUM | |
| SCHEMBL7066781 | 0.79 | CYP1A2 (0.42) | ALDH1A1LMNASMN1; SMN2NOTUM | |
| SCHEMBL7066564 | 0.79 | MMP1 (0.40) | ALDH1A1LMNASMN1; SMN2NOTUM | |
| SCHEMBL7069876 | 0.78 | PPARG (0.43) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | PPARA 3/4885PPARG 1/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.